Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Cell Cycle/Checkpoint >> Aurora Kinase

Aurora Kinase

Aurora kinases are a family of serine-threonine kinases of three highly homologous members, including aurora A kinase, aurora B kinase and aurora C kinase, which are responsible for chromosome assembly and segregation during mitosis. Aurora kinases are characterized by two domains: a regulatory domain in the NH2 terminus and a catalytic domain in the COOH terminus, in which an A-Box and a D-Box found correspondingly in each domain are responsible for protein degradation. Aurora A kinase plays an important role in centrosome function and duplication, mitotic entry and bipolar spindle assembly; while Aurora B kinase is the catalytic component of the chromosomal passenger complex regulating the accurate segregation of the chromatids at mitosis, histone modification and cytokinesis. Aurora C kinase is less studied and expressed restrictedly in the testes.

Products for  Aurora Kinase

  1. Cat.No. Product Name Information
  2. GC35216 AAPK-25 AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3Ser10 phosphorylation and followed by a surge in apoptosis. AAPK-25 targets Aurora-A, -B, and -C with Kd values ranging from 23-289 nM, as well as PLK-1, -2, and -3 with Kd values ranging from 55-456 nM. AAPK-25 Chemical Structure
  3. GC72964 Aurkin A Aurkin A is an allosteric inhibitor for the interaction between Aurora A Kinase (also known also Aurka) and TPX2, through targeting the TPX2 binding sites with Kd of 3.77 μM. Aurkin A Chemical Structure
  4. GC33379 Aurora B inhibitor 1 Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor extracted from patent WO2007059299A1, compound 1-3, has a Ki value of <0.010 uM. Aurora B inhibitor 1 Chemical Structure
  5. GC38441 Aurora Kinase Inhibitor 3 A potent inhibitor of Aurora A kinase Aurora Kinase Inhibitor 3 Chemical Structure
  6. GC67899 Aurora kinase inhibitor-8 Aurora kinase inhibitor-8 Chemical Structure
  7. GC73375 Aurora Kinases-IN-3 Aurora Kinases-IN-3 (Compound 15a) is an orally active AURKB inhibitor that elicits an AURKB-suppressive activity by disrupting the mitotic localization of AURKB. Aurora Kinases-IN-3 Chemical Structure
  8. GC17828 BI-847325 dual inhibitor of MEK and Aurora kinases BI-847325 Chemical Structure
  9. GC19092 CCT241736 CCT241736 is a potent and orally bioavailable dual FLT3 and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A Kd, 7.5 nM, IC50, 38 nM; Aurora-B Kd, 48 nM), FLT3 kinase (Kd, 6.2 nM), and FLT3 mutants including FLT3-ITD (Kd, 38 nM) and FLT3(D835Y) (Kd, 14 nM). CCT241736 Chemical Structure
  10. GC35651 Cenisertib

    AS-703569; R-763

     Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia. Cenisertib Chemical Structure
  11. GC68147 dAURK-4 hydrochloride dAURK-4 hydrochloride Chemical Structure
  12. GC74000 DBPR728 DBPR728 is an acyl prodrug of 6K465 that carries fewer drogen bond donors. DBPR728 Chemical Structure
  13. GC73753 EGFR/AURKB-IN-1 EGFR/AURKB-IN-1 (compound 7) is a dual-targeted EGFR/AURKB inhibitor, and inhibits the phpsphorylations of L858R EGFR and AURKB with IC50s of 0.07 and 1.1, respectively. EGFR/AURKB-IN-1 Chemical Structure
  14. GC69068 ENMD-2076 Tartrate

    ENMD-2076 Tartrate is a multi-target kinase inhibitor that inhibits Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src and PDGFRα with IC50 values of 1.86, 14, 58.2, 15.9, 92.7, 70.8 ,20.2 and 56.4 nM respectively.

     ENMD-2076 Tartrate Chemical Structure
  15. GC34159 Ilorasertib (ABT-348)

    ABT-348

     Ilorasertib (ABT-348) (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib (ABT-348) also is a potent VEGF, PDGF inhibitor. Ilorasertib (ABT-348) has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Ilorasertib (ABT-348) Chemical Structure
  16. GC38519 Ilorasertib hydrochloride

    ABT-348 hydrochloride

     Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Ilorasertib hydrochloride Chemical Structure
  17. GC73744 JAB-2485 JAB-2485 is a potent and selective Aurora kinase A (AURKA) inhibitor, with an IC50 of 0.33 nM. JAB-2485 Chemical Structure
  18. GC33057 LY3295668 (AK-01)

    AK-01

     LY3295668 (AK-01) (AK-01) is a potent, orally active and highly specific Aurora-A kinase inhibitor, with Ki values of 0.8 nM and 1038 nM for AurA and AurB, respectively. LY3295668 (AK-01) Chemical Structure
  19. GC10442 MK-8745 Aurora A inhibitor,potent and selective MK-8745 Chemical Structure
  20. GC34692 NU6140 A Cdk2 inhibitor NU6140 Chemical Structure
  21. GC37606 SCH-1473759 hydrochloride SCH-1473759 hydrochloride is an aurora inhibitor with IC50s of 4 and 13 nM for aurora A and B, respectively. SCH-1473759 hydrochloride Chemical Structure
  22. GC25940 SNS-314 SNS-314 is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively. It is less potent to Trk A/B, Flt4, Fms, Axl, c-Raf and DDR2. Phase 1. SNS-314 Chemical Structure
  23. GC70030 Tinengotinib

    Tinengotinib is a regulator of one or more protein kinases, such as Aurora kinase and VEGFR kinase. Tinengotinib has the potential to study diseases mediated by these kinase abnormalities, especially cancer-related diseases (excerpt from patent WO2018108079A1).

     Tinengotinib Chemical Structure

22 Item(s)

per page

Set Descending Direction